| Title |
Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer
|
|---|---|
| Published in |
Lung Cancer: Targets and Therapy, August 2014
|
| DOI | 10.2147/lctt.s37981 |
| Pubmed ID | |
| Authors |
Irene Stasi, Federico Cappuzzo |
| Abstract |
Bavituximab is a an unconjugated, chimeric immunoglobulin G1 (IgG1) monoclonal antibody directed against the phosphatidylserine (PS) expressed on tumor endothelium, with a specific mechanism of action. PS is an anionic membrane phospholipid, physiologically restricted to the internal membrane leaflet; various pathophysiologic processes cause the exposure of PS on the external membrane leaflet. Bavituximab, once bound, starts up host effector activities, such as antibody dependent cellular cytotoxicity, causing vessel destruction and enhancing antitumor immunity. Phase I clinical trials of bavituximab administered as monotherapy or in combination with other chemotherapeutic agents in adults with pretreated solid tumors have been accomplished, indicating that bavituximab can be safely dispensed weekly, with a recommended dose of 1 and 3 mg/kg. A Phase II randomized, placebo-controlled trial of bavituximab plus docetaxel, in the second-line therapy setting of locally advanced or metastatic non-small-cell lung cancer, has been conducted and recently presented, suggesting a clinical benefit of the combination, with an overall response rate of 17% and median overall survival of more than 11 months. A Phase III trial is currently ongoing. Bavituximab has been studied in combination with platinum-based doublets with promising results. In the present paper we summarize the preclinical development and clinical experience with bavituximab in non-small-cell lung cancer. |
Mendeley readers
The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 4% |
| Unknown | 23 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 7 | 29% |
| Student > Ph. D. Student | 5 | 21% |
| Researcher | 4 | 17% |
| Other | 2 | 8% |
| Lecturer | 2 | 8% |
| Other | 1 | 4% |
| Unknown | 3 | 13% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 7 | 29% |
| Medicine and Dentistry | 6 | 25% |
| Nursing and Health Professions | 3 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
| Immunology and Microbiology | 1 | 4% |
| Other | 3 | 13% |
| Unknown | 3 | 13% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 April 2018.
All research outputs
#8,261,140
of 25,368,786 outputs
Outputs from Lung Cancer: Targets and Therapy
#40
of 128 outputs
Outputs of similar age
#75,180
of 240,202 outputs
Outputs of similar age from Lung Cancer: Targets and Therapy
#1
of 2 outputs
Altmetric has tracked 25,368,786 research outputs across all sources so far. This one has received more attention than most of these and is in the 66th percentile.
So far Altmetric has tracked 128 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.8. This one has gotten more attention than average, scoring higher than 67% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 240,202 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them